APG279 (Zumilokibart + APG990)
Moderate-to-Severe Atopic Dermatitis
Phase 1Active - fully enrolled
Key Facts
Indication
Moderate-to-Severe Atopic Dermatitis
Phase
Phase 1
Status
Active - fully enrolled
Company
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotech with a mission to reshape the standard of care in inflammatory and immune (I&I) diseases by developing superior, half-life extended antibody therapies. Its lead asset, zumilokibart (APG777), an anti-IL-13, has shown positive Phase 2 data in atopic dermatitis and is advancing in asthma and eosinophilic esophagitis. The company's strategy leverages a proprietary FcRn engineering platform to create less frequent dosing regimens and is pursuing both monotherapy and novel combination approaches to capture significant share in large, validated markets.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Regulatory Review |
| Amlitelimab | Sanofi | Phase 3 |
| Zumilokibart (APG777) | Apogee Therapeutics | Phase 2 |
| Ebglyss/Lebrikizumab | Almirall | Marketed/Registration |
| IDgenix (AdvanceAD Tx) | Castle Biosciences | Commercial/Early Launch |
| Rademikibart (CBP-201) | Connect Biopharma | Phase 3 |